Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt ...
A large matched cohort study using U.S. electronic health records finds that patients with pityriasis rubra pilaris have significantly higher odds of leukemia and lymphoma than matched psoriasis ...
Krystal Biotech Inc. KRYS on Thursday released a clinical update for its intratumoral immunotherapy, KB113. The treatment ...
Symptoms are often mistaken for irritation, thrush or an STI, delaying proper treatment. Campaigners say the taboo around ...
New mechanistic research and clinician-reported real-world experience adds to the evolving evidence base for birch ...
An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease ...
Yale School of Medicine will jointly lead a new national research consortium focused on epidermal differentiation disorders, ...
Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...
A Japanese case report of co-localized psoriasis and vitiligo reveals that IL-23 blockade cleared psoriasis but not vitiligo, ...
'I thought it was just me!' ...
Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug ...
FDA’s Rare Disease Evidence Principles (RDEP) process aims to provide greater speed and predictability in the review of therapies for rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results